MétaCan
Menu
Back to cohort
Record W2753716024 · doi:10.1177/1352458517728812

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

2017· article· en· W2753716024 on OpenAlexafffund
Tomáš Kalinčík, Vilija Jokubaitis, Tim Spelman, Dana Horáková, Eva Havrdová, María Trojano, Jeannette Lechner‐Scott, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Claudio Solaro, François Grand’Maison, Raymond Hupperts, Julie Prévost, Patrizia Sola, Diana Ferraro, Murat Terzi, Ernest Butler, Mark Slee, Allan G. Kermode, Marzena J. Fabis‐Pedrini, Pamela McCombe, Michael Barnett, Cameron Shaw, Suzanne Hodgkinson, Helmut Butzkueven

Bibliographic record

VenueMultiple Sclerosis Journal · 2017
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsCegep de Saint JeromeClinique Neuro-OutaouaisCentre intégré de santé et de services sociaux de Chaudière-AppalachesUniversité de MontréalHôpital Notre-Dame
FundersNational Health and Medical Research CouncilSanofi GenzymeBayer HealthCareMultiple Sclerosis SocietyCanadian Institutes of Health ResearchTeva Pharmaceutical IndustriesMultiple Sclerosis Society of CanadaUniverzita Karlova v PrazeFondazione Italiana Sclerosi MultiplaBiogenSanofi
KeywordsFingolimodNatalizumabMedicineMultiple sclerosisCladribineInternal medicineGastroenterologyImmunology

Abstract

fetched live from OpenAlex

OBJECTIVE: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolimod or natalizumab. METHODS: We identified all patients with relapse-onset multiple sclerosis, exposure to the study therapies and ⩾1-year on-treatment follow-up from MSBase. Three pairwise propensity score-matched analyses compared treatment outcomes over 1 year. The outcomes were hazards of first relapse, disability accumulation and disability improvement events. Sensitivity analyses were completed. RESULTS: The cohorts consisted of 37 (cladribine), 1940 (interferon), 1892 (fingolimod) and 1410 patients (natalizumab). The probability of experiencing a relapse on cladribine was lower than on interferon ( p = 0.05), similar to fingolimod ( p = 0.31) and higher than on natalizumab ( p = 0.042). The probability of disability accumulation on cladribine was similar to interferon ( p = 0.37) and fingolimod ( p = 0.089) but greater than natalizumab ( p = 0.021). The probability of disability improvement was higher on cladribine than interferon ( p = 0.00017), fingolimod ( p = 0.0025) or natalizumab ( p = 0.00099). Sensitivity analyses largely confirmed the above results. CONCLUSION: Cladribine is an effective therapy for relapse-onset multiple sclerosis. Its effect on relapses is comparable to fingolimod and its effect on disability accrual is comparable to interferon β and fingolimod. Cladribine may potentially associate with superior recovery from disability relative to interferon, fingolimod and natalizumab.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.010
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow), Science and technology studies, Scholarly communication
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.629
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.010
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0040.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.261
GPT teacher head0.352
Teacher spread0.092 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations44
Published2017
Admission routes2
Has abstractyes

Explore more

Same venueMultiple Sclerosis JournalSame topicMultiple Sclerosis Research StudiesFrench-language works237,207